[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2505532C2 - Соединение - Google Patents

Соединение Download PDF

Info

Publication number
RU2505532C2
RU2505532C2 RU2009139443/04A RU2009139443A RU2505532C2 RU 2505532 C2 RU2505532 C2 RU 2505532C2 RU 2009139443/04 A RU2009139443/04 A RU 2009139443/04A RU 2009139443 A RU2009139443 A RU 2009139443A RU 2505532 C2 RU2505532 C2 RU 2505532C2
Authority
RU
Russia
Prior art keywords
compound according
acetyl
ome
oph
compound
Prior art date
Application number
RU2009139443/04A
Other languages
English (en)
Other versions
RU2009139443A (ru
Inventor
Маттью ЛИЗ
Фабрис ЖУРДАН
Мериел КИМБЕРЛИ
Атул ПУРОХИТ
Майкл Джон Рид
Барри Виктор Ллойд Поттер
Original Assignee
Стерикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стерикс Лимитед filed Critical Стерикс Лимитед
Publication of RU2009139443A publication Critical patent/RU2009139443A/ru
Application granted granted Critical
Publication of RU2505532C2 publication Critical patent/RU2505532C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Настоящее изобретение относится к области органической химии. Предложены соединение формулы (I), где А выбран из CH2 и C=O; B выбран из CH2, C=O и -S(=O)2-; R1 представляет собой -OSO2NH2; R2 выбран из С1-С6-алкоксигрупп; R3 представляет собой
Figure 00000256
где каждый R4, R5, R6, R7 и R8 независимо выбран из H, -OH, C1-C6-алкила, -O-C1-C5-алкила, -OPh, -O-CF3, ацила, -O-ацила, -NH-ацетила, -OSO2NH2, -NH2, -CN, -NO2 и галогенов; где R24 и R25 независимо выбраны из Н и -СН3; и каждый R27 и R28 представляет собой Н, и фармацевтическая композиция, содержащая соединение формулы (I), которая предназначена для предотвращения и/или ингибирования роста опухоли. 3 н. и 7 з.п. ф-лы, 2 ил., 1 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175
Figure 00000176
Figure 00000177
Figure 00000178
Figure 00000179
Figure 00000180
Figure 00000181
Figure 00000182
Figure 00000183
Figure 00000184
Figure 00000185
Figure 00000186
Figure 00000187
Figure 00000188
Figure 00000189
Figure 00000190
Figure 00000191
Figure 00000192
Figure 00000193
Figure 00000194
Figure 00000195
Figure 00000196
Figure 00000197
Figure 00000198
Figure 00000199
Figure 00000200
Figure 00000201
Figure 00000202
Figure 00000203
Figure 00000204
Figure 00000205
Figure 00000206
Figure 00000207
Figure 00000208
Figure 00000209
Figure 00000210
Figure 00000211
Figure 00000212
Figure 00000213
Figure 00000214
Figure 00000215
Figure 00000216
Figure 00000217
Figure 00000218
Figure 00000219
Figure 00000220
Figure 00000221
Figure 00000222
Figure 00000223
Figure 00000224
Figure 00000225
Figure 00000226
Figure 00000227
Figure 00000228
Figure 00000229
Figure 00000230
Figure 00000231
Figure 00000232
Figure 00000233
Figure 00000234
Figure 00000235
Figure 00000236
Figure 00000237
Figure 00000238
Figure 00000239
Figure 00000240
Figure 00000241
Figure 00000242
Figure 00000243
Figure 00000244
Figure 00000245
Figure 00000246
Figure 00000247
Figure 00000248
Figure 00000249
Figure 00000250
Figure 00000251
Figure 00000252
Figure 00000253

Claims (10)

1. Соединение формулы I:
Figure 00000254

где A выбран из CH2 и C=O;
B выбран из CH2, C=O и -S(=O)2-;
R1 представляет собой -OSO2NH2;
R2 выбран из C1-C6-алкоксигрупп;
R3 представляет собой
Figure 00000255

где каждый R4, R5, R6, R7 и R8 независимо выбран из H, -OH, C1-C6-алкила, -O-C1-C5-алкила, -OPh, -O-CF3, ацила, -O-ацила, -NH-ацетила, -OSO2NH2, -NH2, -CN, -NO2 и галогенов;
где R24 и R25 независимо выбраны из H и -CH3;
и каждый R27 и R28 представляет собой H.
2. Соединение по п.1, где R2 представляет собой метоксигруппу.
3. Соединение по п.1, где каждый R4, R5, R6, R7 и R8 независимо выбран из H, -OH, Me, Et, -ОМе, -OEt, -OPh, -O-iPr, -OCF3, F, Cl, -O-ацетила, -NH-ацетила, -O-SO2NH2, -NH2, -CN и -NO2.
4. Соединение по п.1, где R4 выбран из H, -OH и -CN.
5. Соединение по п.1, где R4 выбран из H, -OH, -OMe и -CN.
6. Соединение по п.1, где R5 выбран из H, -OH, Me, Et, -OMe, -OEt, -OPh, -O-iPr, -OCF3, F, Cl, -O-ацетила, -NH-ацетила, -O-SO2NH2, -NH2, -CN и -NO2.
7. Соединение по п.1, где R6 выбран из H, -OMe и -CN.
8. Соединение по п.1, где R7 выбран из H и -OMe.
9. Фармацевтическая композиция, предназначенная для предотвращения и/или ингибирования роста опухоли, которая включает:
(а) соединение по любому из пп.1-8, и
(б) фармацевтически приемлемый носитель, разбавитель, эксципиент или адъювант.
10. Применение соединения по любому из пп.1-8 для изготовления лекарственного средства для предотвращения и/или ингибирования роста опухоли.
RU2009139443/04A 2007-03-28 2008-03-27 Соединение RU2505532C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706072.6 2007-03-28
GBGB0706072.6A GB0706072D0 (en) 2007-03-28 2007-03-28 Compound
PCT/GB2008/001072 WO2008117061A2 (en) 2007-03-28 2008-03-27 Tetrahydroisoquinolines as tumour growth inhibitors

Publications (2)

Publication Number Publication Date
RU2009139443A RU2009139443A (ru) 2011-05-10
RU2505532C2 true RU2505532C2 (ru) 2014-01-27

Family

ID=38050412

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009139443/04A RU2505532C2 (ru) 2007-03-28 2008-03-27 Соединение

Country Status (11)

Country Link
US (1) US8394825B2 (ru)
EP (1) EP2155192B1 (ru)
JP (1) JP2010522735A (ru)
KR (1) KR20090126312A (ru)
CN (1) CN101677993A (ru)
AU (1) AU2008231569A1 (ru)
CA (1) CA2679267C (ru)
GB (1) GB0706072D0 (ru)
IL (1) IL200596A0 (ru)
RU (1) RU2505532C2 (ru)
WO (1) WO2008117061A2 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
NO3175985T3 (ru) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
TWI530485B (zh) * 2011-09-29 2016-04-21 Mitsui Chemicals Agro Inc ３，４－二氫異喹啉衍生物之製造方法
JP2016513726A (ja) * 2013-03-15 2016-05-16 レクサン ファーマシューティカルズ インコーポレイテッド がん細胞成長阻害剤としてのテトラヒドロイソキノリン−２−イル−（キナゾリン−４−イル）メタノン化合物
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
RU2727169C2 (ru) 2013-11-18 2020-07-21 Форма Терапеутикс Инк. Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
SG11201803242TA (en) 2015-10-29 2018-05-30 Effector Therapeutics Inc Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
CN106146416B (zh) * 2016-08-01 2019-02-19 河南大学 氮取代3-氧代-6-取代四氢喹喔啉结构化合物、其制备方法及其医药用途
CN110719781A (zh) 2017-02-14 2020-01-21 效应治疗股份有限公司 取代的哌啶MnK抑制剂及其相关方法
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN106966969B (zh) * 2017-03-29 2019-11-19 南阳师范学院 一种生物碱化合物及其制备方法和用途
JP2022505846A (ja) 2018-10-24 2022-01-14 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ阻害剤の結晶形態
KR20220156535A (ko) 2020-02-07 2022-11-25 가셔브룸 바이오, 인크. 헤테로사이클릭 glp-1 작용제
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227986A1 (en) * 1985-12-09 1987-07-08 Banyu Pharmaceutical Co., Ltd. Isoindoline derivatives and processes for their preparation
US4717724A (en) * 1983-03-10 1988-01-05 Hoechst Aktiengesellschaft 1-(1,3-dioxolan-2-ylmethyl)azoles, their salts and their use
JPH06135935A (ja) * 1992-10-24 1994-05-17 Fuji Kagaku Kogyo Kk 新規なナフタレン誘導体およびその中間体
JPH06135936A (ja) * 1992-10-24 1994-05-17 Fuji Kagaku Kogyo Kk 新規なナフタレン誘導体及びその中間体
WO1998017648A1 (en) * 1996-10-18 1998-04-30 Xenova Limited Anthranilic acid derivatives as multi drug resistance modulators
WO1999062882A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Kg Substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
RU2212405C2 (ru) * 1997-05-13 2003-09-20 Хехст Акциенгезелльшафт Замещенные 6- и 7-аминотетрагидроизохинолин-карбоновые кислоты
WO2004065379A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2006097323A1 (en) * 2005-03-18 2006-09-21 Lutz Weber TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301863A (ja) * 1987-01-13 1988-12-08 Banyu Pharmaceut Co Ltd イソインドリン誘導体の製造法、並びに新規なその中間体及びその製造法
US4958029A (en) * 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
CA2103367A1 (en) * 1991-05-20 1992-11-21 Akihide Koda Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
GB9118478D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9422777D0 (en) 1994-11-11 1995-01-04 Imperial College Assay
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
ES2322877T3 (es) 1996-08-30 2009-06-30 Human Genome Sciences, Inc. Interleucina 19.
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
ES2217428T3 (es) 1996-09-25 2004-11-01 Ss Pharmaceutical Co., Ltd. Derivados de vinilpiridina sustituidos y medicamentos que los contienen.
US6479495B1 (en) * 1997-09-29 2002-11-12 Aventis Pharmaceuticals Inc. Aminoalkylphenol derivatives and related compounds
WO1999050453A1 (fr) 1998-03-26 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Procede servant a rechercher des inhibiteurs de steroide sulfatase
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
MXPA04004802A (es) 2001-11-21 2004-08-11 Sterix Ltd Derivados del 1,2,4-triazol que contienen un grupo sulfamato como inhibidores de aromatasa.
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20080033007A1 (en) * 2002-03-13 2008-02-07 Miller Duane D Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy
JP2003313168A (ja) 2002-04-18 2003-11-06 Kirin Brewery Co Ltd Ｂｃｌ−２阻害活性を有する化合物およびその化合物のスクリーニング方法
CN1187332C (zh) * 2002-04-26 2005-02-02 中国科学院上海有机化学研究所 四氢异喹啉羟肟酸磺酰胺类化合物、合成方法及其用途
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
JP4464814B2 (ja) * 2002-05-14 2010-05-19 アバーント・ファーマシューティカルズ・（インディア）・リミテッド アントラニル酸誘導体の水和物の製造方法
EP1556357A4 (en) * 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
US7115598B2 (en) * 2003-04-25 2006-10-03 Ortho-Mcneil Pharmaceutical, Inc. Substituted 1,4-diazepines and uses thereof
DK1663185T3 (da) * 2003-09-22 2009-04-06 Onepharm Res & Dev Gmbh Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab
KR100557093B1 (ko) * 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
DE102004031850A1 (de) 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN101155588A (zh) * 2005-04-12 2008-04-02 默克公司 Akt活性的抑制剂
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
CN101020689A (zh) * 2007-03-12 2007-08-22 复旦大学 1－(3－吲哚基)－6,7－亚甲二氧基－1,2,3,4－四氢异喹啉衍生物、制备方法和用途

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717724A (en) * 1983-03-10 1988-01-05 Hoechst Aktiengesellschaft 1-(1,3-dioxolan-2-ylmethyl)azoles, their salts and their use
EP0227986A1 (en) * 1985-12-09 1987-07-08 Banyu Pharmaceutical Co., Ltd. Isoindoline derivatives and processes for their preparation
JPH06135935A (ja) * 1992-10-24 1994-05-17 Fuji Kagaku Kogyo Kk 新規なナフタレン誘導体およびその中間体
JPH06135936A (ja) * 1992-10-24 1994-05-17 Fuji Kagaku Kogyo Kk 新規なナフタレン誘導体及びその中間体
WO1998017648A1 (en) * 1996-10-18 1998-04-30 Xenova Limited Anthranilic acid derivatives as multi drug resistance modulators
RU2212405C2 (ru) * 1997-05-13 2003-09-20 Хехст Акциенгезелльшафт Замещенные 6- и 7-аминотетрагидроизохинолин-карбоновые кислоты
WO1999062882A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Kg Substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
WO2004065379A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2006097323A1 (en) * 2005-03-18 2006-09-21 Lutz Weber TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER
WO2006117669A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARA H ET AL: "Studies on tetrahydroisoquinolines. XXIV. A synthesis of dibenzo[c,f]-1-azabicyclo[3.3.1]nonanes and dibenzo[d,g]-1-azabicyclo[4.3.1]decanes" CHEMICAL AND PHARMACEUTICAL BULLETIN 1985 JP, vol.33, no.7, 1985, pages 2705-2711. *
HARA H ET AL: "Studies on tetrahydroisoquinolines. XXIV. A synthesis of dibenzo[c,f]-1-azabicyclo[3.3.1]nonanes and dibenzo[d,g]-1-azabicyclo[4.3.1]decanes" CHEMICAL AND PHARMACEUTICAL BULLETIN 1985 JP, vol.33, no.7, 1985, pages 2705-2711. SUAU RAFAEL ET AL: "N-benzylisoquinoline alkaloids from Ceratocapnos heterocarpa" PHYTOCHEMISTRY (OXFORD), vol.36, no.1, 1994, pages 241-243. HARA, HIROSHI ET AL: "A novel synthesis of dibenzo[c,f]-1-azabicyclo[3.3.1]nonanes" HETEROCYCLES, 1981, 15(2), 907-910. IWASA, KINUKO ET AL: "Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents" BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9(11), 2871-2884. *
HARA, HIROSHI ET AL: "A novel synthesis of dibenzo[c,f]-1-azabicyclo[3.3.1]nonanes" HETEROCYCLES, 1981, 15(2), 907-910. *
IWASA, KINUKO ET AL: "Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents" BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9(11), 2871-2884. *
SUAU RAFAEL ET AL: "N-benzylisoquinoline alkaloids from Ceratocapnos heterocarpa" PHYTOCHEMISTRY (OXFORD), vol.36, no.1, 1994, pages 241-243. *

Also Published As

Publication number Publication date
KR20090126312A (ko) 2009-12-08
RU2009139443A (ru) 2011-05-10
IL200596A0 (en) 2010-05-17
CA2679267A1 (en) 2008-10-02
US8394825B2 (en) 2013-03-12
US20100222299A1 (en) 2010-09-02
GB0706072D0 (en) 2007-05-09
CN101677993A (zh) 2010-03-24
WO2008117061A3 (en) 2009-05-14
EP2155192A2 (en) 2010-02-24
JP2010522735A (ja) 2010-07-08
WO2008117061A2 (en) 2008-10-02
AU2008231569A1 (en) 2008-10-02
EP2155192B1 (en) 2016-09-28
CA2679267C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
RU2505532C2 (ru) Соединение
RU2409562C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
RU2409572C2 (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
RU2391346C2 (ru) 39-дезметокси производные рапамицина
RU2397976C2 (ru) Производные бензамидов и гетероаренов
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
RU2003137565A (ru) Производные n-формилгидроксиламина в качестве ингибиторов пептидилдеформил азы (pdf)
RS53843B1 (en) BIS (FLUOROALKYL) -1,4-BENZODIAZEPINONE COMPOUNDS
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2010509379A5 (ru)
RU2502730C2 (ru) Сульфонамидные соединения и их применение
JP2018510139A5 (ru)
AR073548A1 (es) Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico
RU2007123235A (ru) Противоопухолевые соединения
JP2012502112A5 (ru)
RS51725B (en) N-METHYLAMINOMETHYL ISOINDOL COMPOUNDS AND COMPOSITIONS CONTAINING THEM AND USING THE SAME
JP2010536887A5 (ru)
CO5160273A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos derivados de quinazolina
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
RU2019121926A (ru) Ингибитор CDK4/6
JP2011520815A5 (ru)
RU2013119129A (ru) Органические соединения
EA200702331A1 (ru) Способ получения стробилуринового фунгицида, соединение и композиция
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160328